DOP17 HIV infection is associated with a less aggressive phenotype of inflammatory bowel disease. A multicenter study based on the ENEIDA registry

Abstract Background The coexistence of immune-mediated diseases and non-pharmacological immunosuppression states are rare might determine the natural history disease therapeutic decisions physician. IBD guidelines recommend screening for human immunodeficiency virus (HIV) before starting immunosuppressive treatment, but data on impact HIV infection its management in era biological drugs scarce. Therefore, our aim was to describe phenotype, requirements, prevalence opportunistic infections (OI) patients with coexistent infection. Methods Case-control, retrospective, multicenter study including all available serology ENEIDA registry (a large, prospectively maintained database Spanish Working Group –GETECCU). positive were selected (HIV+) compared seronegative (controls), matched 1:3 by year diagnosis, age, gender type IBD). Demographic, clinical characteristics, OI complications registered. Results Eighty-eight HIV+ 264 controls included. In whole cohort, 81% men, 56.8% had ulcerative colitis (UC), 36.4% Crohns’ (CD) 6.8% unclassified. Median age at diagnosis 38 years (IQR 30-47), median 36 30-42), 46.3% being firstly diagnosed IBD. Among UC patients, a lower proportion extensive (24.5% vs 44.8%; P=0.002), higher proctitis (38.8% vs. 16.6%; P=0.002) than controls, without differences proximal progression (7.7% 7.9%). CD presented colonic involvement (40.6% 12,6%, penetrating behavior (10.7% 25%; ns). extraintestinal manifestations 25.4%; P=0.005). Although it not statistically significant, trend towards hospitalizations (25.6% 35.3%) (6.3% 9.2%) observed. Regarding immunosuppressant (40.5% 58.7%; P=0.003) (28.3% 42.8%; P=0.020) used less frequently among controls. Conversely, rate (38.3% 17.8%; P<0.001) malignancies (12.5% 8.3%, ns) Conclusion seems be associated aggressive phenotype use immunosuppressants biologicals remarkable OI.